Research Article

Protective efficacy of a genetic subunit bacterin against edema disease of swine in mice

Published: December 22, 2015
Genet. Mol. Res. 14 (4) : 18026-18033 DOI: https://doi.org/10.4238/2015.December.22.29
Cite this Article:
X.L. Yang, Y.J. Liu, L.Q. Hu, L.W. Guo, G.P. Liu, B. Wu, H.C. Chen (2015). Protective efficacy of a genetic subunit bacterin against edema disease of swine in mice. Genet. Mol. Res. 14(4): 18026-18033. https://doi.org/10.4238/2015.December.22.29
2,757 views

Abstract

The exotoxin SLT-IIeB from the Escherichia coli Ee strain was expressed in E. coli, and the recombinant protein was purified, mixed with the Ee strain, then emulsified with oil-emulsion adjuvants to obtain a mixed subunit bacterin. Groups of Kunming mice were immunized at weeks 0 and 2, and challenged intraperitoneally with the Ee strain at week 4. Antibodies were detected by ELISA and an agglutination test. After the second immunization, the antibody level increased and the rate of immune protection against the Ee strain was 70 and 91.7% in the subunit bacterin and bacterin groups, respectively. Therefore, the mixed subunit bacterin provided good protection against the homologous Ee strain, which provides a basis for further research, into high-efficacy vaccines against porcine edema disease.

The exotoxin SLT-IIeB from the Escherichia coli Ee strain was expressed in E. coli, and the recombinant protein was purified, mixed with the Ee strain, then emulsified with oil-emulsion adjuvants to obtain a mixed subunit bacterin. Groups of Kunming mice were immunized at weeks 0 and 2, and challenged intraperitoneally with the Ee strain at week 4. Antibodies were detected by ELISA and an agglutination test. After the second immunization, the antibody level increased and the rate of immune protection against the Ee strain was 70 and 91.7% in the subunit bacterin and bacterin groups, respectively. Therefore, the mixed subunit bacterin provided good protection against the homologous Ee strain, which provides a basis for further research, into high-efficacy vaccines against porcine edema disease.